Vancouver, British Columbia – March 24, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that its French partner, Biogalenys, observed positive effects of Sirona’s glycoprotein SBM-TFC-837 on human fibroblasts in preliminary, in vitro, studies in response to the stressed condition of ultraviolet (UV) radiation.
The results of these studies demonstrated a dramatic increase in percent cell viability over time with SBM-TFC-837, which suggests our glycoprotein plays an important role in protection against UV induced cell death.
“These results are tremendously exciting and further add to our previously reported results which demonstrated that our glycoproteins were protective against extreme conditions,” said Attila Hajdu, Chief Business Development officer of Sirona Biochem. “We have added this new data to our existing patent and have recently generated significant interest from major pharmaceutical companies that recognize the value that our fluorination platform technology provides.” Further studies are ongoing and will continue to assess cell stressors and viability. The compounds may have applications in:
- Anti-aging cosmetic product since 80% of visible aging is directly related to cell death
- Regenerative and protective cosmetic or pharmaceutical product for healing, wound care, hypothermic protection, sunscreen, post burn / radiotherapy
- Regenerative and protective pharmaceutical product against stress response in renal reperfusion and the improvement of engraftment
- Pharmaceutical product used in organ transplantation solution (for example Wisconsin solution)
- Regenerative and preservative product for preservation of stem cells, β-islet cells, red blood cells, adipocytes and platelets as well as tissues including reconstituted human epithelial cells, skin explants and cornea
- Preservative for vaccines
The global anti-aging market is forecast to reach up to $345.8 billion US in 2018 from $249.3 billion in 2012. The related market for regenerative medicine, which aims to restore functional ability to tissues and organs, is set to hit $67.6 billion US in 2020.
The anti-aging project is supported by Bpifrance and the region Haute Normandie.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.